Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMCOpen access

TFC-1326 Compound Reduces Clinical Signs of Skin Aging. Evidence From In Vitro Human Adipose and Skin Models and Pilot Clinical Trial

Deliencourt-Godefroy G., Legoedec J., Bourdens M., Juin N., Nguyen LT., Branchet MC.

Clinical Trial with a reported sample of 20 on Skin Aging, published in J Cosmet Dermatol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
J Cosmet Dermatol (2025)
Reported sample size
20
Source database
Europe PMC
PMID
39552205
PMCID
PMC11845922
DOI
10.1111/jocd.16679
Citations
1

Abstract (original English)

Background Anti-freeze Glycoproteins (AFGPs) were described to preserve biological materials and protect them from different stresses. Aims The effects of a synthetic anti-freeze glycoprotein-based compound, TFC-1326, on human skin quality and its biological actions were studied. Methods The effects of various concentrations of TFC-1326 on the biology of human preadipocytes, differentiated in the proinflammatory microenvironment, and on human fibroblasts grown in coculture with human mature adipocytes or monocultured in stress conditions were investigated in, in vitro studies. Additionally, the efficacy of a 1% TFC-1326 topical cream was evaluated in a clinical investigation on the skin biology and appearance of 20 women aged between 40 and 65 years throughout 84 days of application. Results The in vitro studies revealed that TFC-1326 mitigated the deleterious effects of a proinflammatory cytokine cocktail produced by human macrophages, by restoring preadipocyte adipogenic capacity and by reducing their fibroinflammatory state. TFC-1326 also stimulated the proliferative capacity of dermal fibroblasts co-cultured with mature adipocytes as well as their production of hyaluronic acid and procollagen type I, while decreasing IL6 secretion and increasing fibroblast viability. Furthermore, daily 1% TFC-1326 topical cream application, measurably improved skin radiance and laxity, as w

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
Cells, CulturedAdipocytesFibroblastsMacrophagesSkinHumansCoculture TechniquesAdministration, CutaneousPilot ProjectsCell Proliferation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research